# US 8,278,263 B2 · Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase D and raptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,263 B2
- Document ID: US8278263B2
- Status: Granted
- Kind: B2
- Application number: 12/374,262
- Filed: 2007-08-03
- Published: 2010-07-22
- Granted: 2012-10-02
- Earliest claimed: 2006-08-04
- Assignees: Postech Academy-Industry Foundation
- Inventors: Sung-Ho Ryu; Pann-Ghill Suh; Sang-Hoon Ha; Do-Hyung Kim; Il-Shin Kim; Jung-Hwan Kim; Mi-Nam Lee; Hyun-Ju Lee; Jong Heon Kim; Sung-Key Jang; Tae-Hoon Lee
- Web page: https://patentgrep.com/patent/US8278263B2

## CPC

- A61K 38/1709: {from mammals}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 9/20: Triglyceride splitting, e.g. by means of lipase
- C12Y 301/04004: Phospholipase D (3.1.4.4)
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

## Claims

### Claim 1

A method of inhibiting mTOR by inhibiting the interaction between PLD2 and raptor, thereby inhibiting the formation of a complex of PLD2 and mTOR through raptor (PLD/raptor/mTOR complex), comprising the step of inactivating a raptor binding domain of PLD2 by substitution of one or more amino acids of SEQ ID NO: 4 comprised in the raptor binding domain of PLD2, with at least one other amino acid selected from the group consisting of alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, valine, asparagine, cysteine, glutamine, glycine, serine, threonine, tyrosine, aspartic acid, glutamic acid, arginine, histidine, and lysine.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the step of inactivating a raptor binding domain of PLD2 is conducted by substitution of one or more amino acids located in the amino acid sequence of SEQ ID NO: 4 comprised in the raptor binding domain of PLD2, with alanine, or arginine.
